Multiple Sclerosis : Diagnosis and Treatment
Multiple sclerosis (MS) offers important challenges to understanding its complex genetics and molecular and immunological mechanisms, which eventually lead to relapsing and progressive clinical forms and a constellation of clinical manifestations. Along with the progress in knowledge, disease-modify...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04262naaaa2200877uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_78841 | ||
| 005 | 20220224 | ||
| 020 | |a books978-3-0365-3097-0 | ||
| 020 | |a 9783036530970 | ||
| 020 | |a 9783036530963 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-3097-0 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Rivera, Víctor M. |4 edt | |
| 700 | 1 | |a Rivera, Víctor M. |4 oth | |
| 245 | 1 | 0 | |a Multiple Sclerosis : Diagnosis and Treatment |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (192 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Multiple sclerosis (MS) offers important challenges to understanding its complex genetics and molecular and immunological mechanisms, which eventually lead to relapsing and progressive clinical forms and a constellation of clinical manifestations. Along with the progress in knowledge, disease-modifying treatments and new therapeutic molecules have made an impact on the prognosis of the disease. Essential in the diagnostic identification process of MS is the differentiation of this major demyelinating disease with other inflammatory CNS disorders, including Neuromyelitis Optica and MOG antibody disease. MS is more prevalent in women; therefore, pregnancy and post-partum hormonal and immunological changes typically affect the clinical behavior of the disease. This Special Issue of Biomedicines addresses recent advances in the mechanistic genetic and immunological processes of MS, opening more options to future studies and to the consideration of further therapeutic possibilities. The issue discusses the application of modern therapies, including monoclonal antibodies, some still in the process of complete development, and the current strategies managing progressive MS. The aim of this issue is to stimulate basic and clinical research and promote observations on the ever-expanding and complex field of MS. Advancement in the understanding of the mechanisms and the clinical characterizations of this disease should result in improved therapeutic outcomes that reduce neurological and cognitive disability commonly associated with progressive disease. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a multiple sclerosis | ||
| 653 | |a genetics | ||
| 653 | |a disease modifying therapies | ||
| 653 | |a generic medicines | ||
| 653 | |a association study | ||
| 653 | |a reactive oxygen species | ||
| 653 | |a NADPH oxidase | ||
| 653 | |a CYBB | ||
| 653 | |a autoimmunity | ||
| 653 | |a axon | ||
| 653 | |a cortex | ||
| 653 | |a demyelination | ||
| 653 | |a mitochondria | ||
| 653 | |a myelin | ||
| 653 | |a neurodegeneration | ||
| 653 | |a oligodendrocyte | ||
| 653 | |a progressive multiple sclerosis | ||
| 653 | |a daclizumab | ||
| 653 | |a relapsing multiple sclerosis | ||
| 653 | |a CD25 | ||
| 653 | |a innate immune system | ||
| 653 | |a interleukin-2 | ||
| 653 | |a drug reaction with eosinophilia systemic symptoms | ||
| 653 | |a DRESS | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a anti-CD20 | ||
| 653 | |a Ocrevus | ||
| 653 | |a Rituxan | ||
| 653 | |a Tysabri | ||
| 653 | |a clinical trial | ||
| 653 | |a disease modifying therapy | ||
| 653 | |a demyelinating diseases | ||
| 653 | |a cognitive impairment | ||
| 653 | |a cognitive dysfunction | ||
| 653 | |a stem cells | ||
| 653 | |a autologous hematopoietic | ||
| 653 | |a mesenchymal | ||
| 653 | |a neuronal | ||
| 653 | |a induced pluripotent | ||
| 653 | |a human embryonic | ||
| 653 | |a pregnancy | ||
| 653 | |a post-partum | ||
| 653 | |a treatment | ||
| 653 | |a neuromyelitis optica spectrum disorders | ||
| 653 | |a anti-MOG syndrome | ||
| 653 | |a aquaporin 4-IgG | ||
| 653 | |a myelin oligodendrocyte glycoprotein | ||
| 653 | |a remyelination | ||
| 653 | |a outcome measures | ||
| 653 | |a biomarkers | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4935 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78841 |7 0 |z DOAB: description of the publication |